Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So the large BPs are playing their usual game of screwing the startup to the wall to take everything but the crumbs.
It makes one think some smart medium sized BP might not be quite so demanding and give a win-win deal to acquire the rights to the full platform of a drug that has potential that is nearly unlimited.
Medium sized pharmas could handle a few trials easily.
This requires the art of making a deal; does IPIX have the skill to handle such a deal or make it happen?
Right now I see us spinning our wheels (if we are spinning at all)
We already had a Regional Biolab report on the spectrum wide possibilities of Brilacidin for both Covid and all other viruses and they even put out a white paper (or at least a paper preview) about a year and a half ago. We also have Dept of Defense looking into B as possible agent against 20 large and deadly viruses that started about 6 months ago.
So why haven't they done anything since then? Either this is the most dense dept in the govt (right up there with CDC, Barda, etc) IMO or some other hidden reason is keeping them form throwing any money to get B in pill form.
Screw the recent trial with its low dosage angle, they have govt lab findings of the great potential for B and yet they, like all govt, have done nothing.
Dept of Defense has been looking at B for 20 of the worst viruses known since Oct '21 in their biolabs.
They should already have quite the stack of data showing what a powerhouse B is yet we haven't heard a peep out of them. Since all they do is lab work, not on humans, shouldn't have taken this long. Maybe they all are also lawyers and get paid by the hour so they are milking this lab work as long as possible.
Something is just not right when a drug with this potential gets no funds whatsoever from any sources and no BP wants to get the lead-in for acquiring the whole platform by coughing up maybe only a few hundred million. At what they pay for 1 application drugs with many adverse effects, a shown safe drug with a myriad of potential uses should have had some sharp BP sniffing at our door.
As for big names, UCSF is a big name and thus Dr.DeGrado's lab is highly known throughout the medical world IMO.
With the PR last week and this PR Brilacidin should be given to all patients in the USA for Compassionate Use once they show the least inability to shake Covid. Get them on B ASAP!! Nothing to lose for patient and medicine could see if B is the real deal or not, not like the sham trial that simply wasted a year and cost a lot of lives.
I have to go back to Brilacidin having the potential to greatly hurt many BPs financially, some critically, and a concerted effort is being made to squelch the drug. How many CURES has BP produced over the last number of decades? Next to none. All they do is treat the symptoms so you become a user for life. B would change that and that scares the hell out of BP.
Just my take on the matter.
And then some twit takes it down on a $3.55 trade (100 shares) at 15.59.59 - geez, wonder if that was a robotic trade.
Doesn't get much more obvious than that the games being played.
This PR and today's trading was important for far more than just the data analysis results it provided:
1. It showed how closely controlled the share price is. Good news and yet only $19,500 in trades for the day. Controllers were able to show a large drop in the price today for next to nothing. Such blatant control needs no further discussion.
2. It shows the massive drop in price on hyperbolic volume due to the Nov PR telling about failing to meet the primary objective also meant most likely 70-90MM shares or so in volume that day was due to these controlling interests. If not true, the volume today would have been sky high rather than a laughable 550K shares or so.
3. It showed next to nobody follows IPIX at the current time and not all that many any time in the past. If so, volume today would have been larger.
4. It shows that further "investigation to be pursued as will further grant money or govt funding" type PRs will not do squat to move the share price. The only thing we can see that will move the price to any degree is a firm partnership(s) where funding is provided, large grant money from the government is achieved, or an important clinical trial sees excellent success such as a P3 for OM or a P2 for colitis. As I have posted earlier, my belief in fair clinical trials for Brilacidin is scant as this trial was a joke IMO on so many levels thanks to how the FDA allowed it to be set up, the disparity in severity of patients alloted to Brilacidin vs placebo, the ability of placebos to always work far better in blind trials than when they are tested alone (Remsdesivir). etc, etc.
I take as very positive the following excerpt from the recent 10Q (bottom of page 28) because I thought he was given Compassionate Use data since it wasn't part of the trial and he knows from that the data is going to be positive - only reason he would have IMO to have put this line in the 10Q - in fact, the entire paragraph is quite positive:
Given this unmet need, concerning potential future Brilacidin trials in hospitalized COVID-19 patients, the Company is planning to apply to government-sponsored COVID-19 trial platforms. Pursing a biomarker-driven approach, increasing Brilacidin dosing, targeting different patient populations, testing Brilacidin in combination with other drugs (e.g., remdesivir, given strong synergistic in vitro data)—all are areas under consideration. Compassionate use of Brilacidin may also continue.
Right now the Brilacidin Covid trial has been painted a total failure when in fact all they failed was the primary objective and that failure,IMO, was due more to the weak dosage allowed and the limited days of dosings. So I would say the failure should more accurately be said to have been in the trial setup. I blame this setup on the FDA considering the AMA published a paper last April/May that said Covid therapeutic trials were about 95% run at lower dosages than those needed to provide any effectiveness. For some reason the FDA has had it in for therapeutics from the get go regarding Covid and IMO this shows some government officials are being paid off quite handsomely by BP.
Some will greatly disagree with my assessment. We will see who is right when the complete trial data is released. Though the secondary data may be limited in efficacy due to the low dosage I believe the Compassionate Use data will affirm B was effective according to many markers seen in the CU patients such that it should be continued to be studied for further investigation and use at much higher dosing.
Brilacidin is still worth a fortune IMO and maybe the strongest broad spectrum antiviral ever developed, mainly due to its great anti-inflammatory properties and unique multiple MOAs.
What we need IMO is a strong Covid partner to be able to quickly advance it thru the FDA system and help with the costs. Leo tried to do it alone and to date has been highly unsuccessful. Now is the time to get a strong partner and let both them and IPIX share in the financial bonanza B should cause to occur relating to Covid. The world will be much the better when B gets commercialized. Stockholders have been left hanging much, much too long IMO. Get things done now or get new direction at the top.
With these numbers makes me scratch my head why some other BP hasn't come to IPIX with a bid of billions to get B into pill form so they could start raking in billions (with what I believe would be a much, much more effective product).
Even a few billion just for COVID partnership should be a given for a BP with money to burn. Where else could they find such a readily large market with next to no competition?
Throw in the other viruses (as with a guaranteed last bid offering) and the value skyrockets from there.
We partner.
I have to believe that Leo has finally realized he can't do it alone. IPIX will need some heavy lifting by another company to get Brilacidin off the ground.
Not saying he has to partner the whole platform, but get a decent use authorized so it can become widely accepted. Get some dough coming in for the first commercial authorization by the FDA and keep the government stoking the fires of further broad spectrum viral and biological invetigations.
Never forget getting Brilacidin widely investigated and known throughout the medical industry many of us thought was the prime reason B was thrust into the Covid conversation. The other opportunities offered by the recent trial was icing on the cake and still not kaput until we here what the CU results showed (and I think they will show B did very well against the virus).
Now that the world knows vaccines aren't going to end the Covid problem and a very good therapeutic(s) will be needed B is in play to a greater degree than ever IMO and the only thing holding us back is the deep pockets and governmental palm greasing that a heavy hitting partner could provide.
I was expecting this type of shareholder notice as IMO it tells us a lot without Leo having to have disclosed anything. Job well done IMO.
Figure we don't hear anything further until at least week after next but then I believe the lid will be raised on what is cooking behind the scene at the current time.
B is a therapeutic, not a vaccine, as it kills viruses and bacteria instead of building up antibodies and the like to prevent the virus from infecting the body.
B is a synthetic drug, great for preventing cytokines but not great as a vaccine agent since the body doesn't identify it as a threatening agent. Ergo, no working as a vaccine.
Forget the vaccine, B is still the best bet for a broad spectrum antiviral therapeutic (if they give it at the proper treatment levels of dosage) and that will be more than enough to satisfy all shareholders.
The overly dramatic drop in share price due to top line failure was all manufactured by the powers which have been targeting IPIX for years and IMO by the FDA as well.
The government and military in particular know quite well the potential of B and it will have its day soon (though how soon is anyone's guess).
BDD Pharma seems to delve mainly into the dermatology range of products. Brilacidin has always said that dermatology was a strong area in which it should work quite well. Never know, maybe nothing to it or something brewing on the back side. Exciting to know we have so many areas in which B can work.
I will be disappointed if Leo does put out any news this week.
Wait for the New Year to start with PRs, not the off week between Christmas and the New Year.
I am hoping for news on a number of fronts in Jan and a fast start to Q1 2022.
Current non-IPIX events make me realize the recent trial was facing harsh headwinds but they can be overcome if secondary/CU results are favorable. I expect very good CU results, not in terms of patients saved but in reduction of many important Covid indicators while secondary trial results could be very marginal should the reduced dosage and dosings prevented full Brilacidin effect on patients as evidenced by Top Line result. I do expect we see some good secondary results, though they may be quite marginal due to above.
If B had any role regarding this Army vaccine noted in a post by P007 yesterday that would be wonderful. But simply knowing the Army has been so intent on working to solve problems regarding viruses, coupled with the PR stating how the govt would be doing further study of B against 20 major viruses shows that its use as a broad spectrum antiviral is even more important.
I believe the DOD has been doing a great deal of studying of B over the last 2 years and realizes its importance in being a front line treatment for both viral and bacterial problems on an extremely broad scale.
B's anti-inflammatory uses are less known at this time as they will be handled IMO more from a commercial BP side. I hope soon we get a partnership with a BP for this specific segment of the B platform as these problems afflict so many and I only see the FDA allowing a rapid progression of B in this area with BP support.
I no longer believe IPIX going it alone for the spectacular success it deserves for B is the proper path as too much headwinds from deep pocketed foes. Thus, I am all for partnering all segments of the B platform hellbent for leather to get the treatments into the world of medicine ASAP and allow IPIX to still achieve excellent returns for investors.
Covid / B is not the end game for IPIX but still should be an area where it sees great success IMO
IMO the Covid test for Brilacidin was a boxing match in which they tied B's hands prior to entering the ring.
Don't see Leo putting out any news prior to the end of the year as many financial entities are on vacation until the first of 2022.
Wait until everybody gets done with the Holiday Season and then start putting out the news.
Today's PR pretty much validated what I have been preaching since the top line failure - trial was set up poorly (intentional? - IMO yes) and B had no chance of succeeding due to dosage limitation, dosing limitation, and severity of patients.
I put the blame both on IPIX mgt allowing these limitations without requesting an offsetting lower primary objective and FDA/govt individuals receiving heavy lobbying funds by BP.
Those painting the few of us pointing up these limitations as conspiracy geeks were soundly disproved as the follow up data and upcoming Compassionate Use and further secondary objective analysis points out B DID WORK on those even with critical conditions when given the right dosage for the correct number of days.
Bottom line was that the last year for the trial was a near waste - but that was the plan IMO by outside forces to keep B from severely hindering BP revenues. My view of the FDA/govt/medical industry is at an all time low as to trust they are truly working for the good of the general public.
Excited to hear Leo take a more partnering attitude for IPIX as I now believe the powers to be will not allow IPIX to succed by themselves. The BP cash cow must be fed.
Don't see much further action prior to end of year so will back off from IPIX until then.
I am sure those so negatively slanted towards IPIX will not take any time off - as to why that is pretty well known.
Reading the article you posted recently (link attached below)I came across the below paragraph:
"Remdesivir, known also by its brand name "Veklury," is normally used for adults and children over 12 requiring hospitalization for covid-19, and is normally given in a vein by intravenous (IV) infusion one time each day for up to 10 days."
I am of the belief that the FDA limited the dosage far below what IPIX requested for the trial, the patients were mostly very severe with next to no moderate patients, and now we find out that the dosing days for the trial was limited to 3 days for 25% of patients and 5 days for the remaining patients. All in all, both the dosage and dosings were quite limited due to normal dosing for Rems.... so Brilacidin not performing to the level we expected was a given before the trial even began.
Kind of like going hunting with blanks and being disappointed when none of your shots on target were able to bring down your target.
This is why I feel the CU data is the actual part of the testing that will be able to show somewhat what Brilacidin can really do against Covid.
https://www.yahoo.com/finance/gilead-recalls-vials-remdesivir-covid-122120730.html
Nice to think WHO would finally get off their ass and do some real research to solve problems.
Many longs had/have those same questions IMO.
I believe this upcoming week we get some further guidance (to the advantage of IPIX) on trial results with some very positive indications from the Compassionate Use patients as to the anti-inflammation and related type indicators at the higher dosage and longer dosing periods.
Bottom line to me: Trial was run with Brilacidin in handcuffs so a lackluster result was to be expected. I thought Leo should have lowered the main objective bar when he found out the dosage was to be limited.
Main question to me: Why was trial run at a reduced dosage to what IPIX wanted and why would the FDA allow CU to be run at 2 1/2 times the dosage for Compassionate Use if they didn't have a good idea even this greatly increased dosage would not cause any major problems? Another troubling point was that when they stopped the trial after 25% was completed to allow uptick from 3 to 5 days, why wasn't an additional arm started to test at higher dosage for say 30 additional patients if they saw the original dose was not providing the effectiveness they were expecting???
The volume was totally managed on 10 Nov and the nakeds won quite handily from the traders / newbies.
Dosage too low and possibly dosing not often enough the ONLY reason for the failure to reach TL objective IMO.
The placebo doing so well (as happened exactly as in P trial) makes me believe it is hard to find an honest testing site when so much at stake that could really damage BP.
Don't know why news today surprises anybody, it has been stressed on this board since the TL PR.
What don't you understand in it being BOTH anti-viral and antibiotic?
Also anti-fungal, anti-inflammatory, etc?
It is not a one trick pony.
The only possible event IMO that would indicate a possible buyout or major partnership of some kind is if we get some positive results from the secondary endpoints or the Compassionate Use cases and we still have a media blackout. That would be very odd leading one to believe something could be brewing, but I still wouldn't take that to mean there is a definite deal in the works.
If we don't get good results and no media mention, I don't think much can be said one way or the other.
Bottom line is too much talk of a buyout/partnership now leads to many thinking the company failed if it doesn't occur and that is totally misleading IMO. I prefer at this juncture to stay low profile and expect nothing except for further trial results in the next week or so.
What proceeds after that is all open to conjecture.
I found it in the table but looked further down and saw no discussion of Brilacidin anywhere. Don't think much will come out of this article.
From what I have heard much higher dosage and more dosings.
I expect we get some good data from this even if patients didn't fare well due to their greatly advanced stage of Covid.
They had nothing to lose with such critical patients so no need to molly coddle the treatment.
That is why I am incensed with the reluctance to give high dosages for all trial drugs to a limited # of patients in critical condition. They would be volunteers and FDA would get much, much more information that just that from the antiseptic trial protocol. Current system absolutely asinine IMO. Possibly lose a few but save many.
The secondary endpoints examination is important but if the TL failure was due to too low of dosage it might make all secondary outcomes muted as well. So if secondary outcomes negative not that big a deal IMO (though positives to any degree would be large showing B was working for the dosage given).
I believe where the real gold nuggets lay as to data is with the Compassionate Use data. If that data is negative, major major disappointment but positive data will show B is still as viable as ever IMO.
Per PM request, msg sent.
We entered the Covid arena IMO to get Brilacidin investigated much more and we have succeeded more than I could have imagined.
We now know a lot about it, what it can and can't do, and the positives are still very large.
On the other hand, time and money are definitely not on our side. Sure hope we partner with BP soon for B-Covid at whatever we can get as that would really help us with all other areas for which B should be quite strong and speed up trials in all those areas.
Talking with a good poster via Happy Hour PM and he made a real good point regarding the continued validity of Brilacidin in the Covid arena.
Recommend he put it out to the whole board and see what they think as it should show B not out of the running even though it didn't meet TL objective.
I agree. Take whatever we can get for B-Covid w/ a BP as we need some speed for B in this sector which won't happen other than a BP partnership. Once we(in conjunction w/ BP) prove B-Covid IPIX can go alone in IBD, OM, and other areas of interest. But now we need BP money, speed of B advancement, and blessing of FDA.
My overall view of TL was that the dosage was far, far too small to make any difference on these patients that were mainly in the severe category. I understand FDA requested a lower dosage than IPIX wanted. Makes one wonder, at least to me.
All the secondary data you would like to see is expected to be released by the end of the month. Could alter things a bit, especially if Compassionate Use data is also quite good.
Those answers will come by end of month when full analysis numbers are expected to be given.
Pill necessary as Kevetrin leavs the body so fast a pill is needed for easy patient delivery as opposed to them being hooked up to an IV for a long period.
This is a great trait as it prevents systemic buildup of Kevetrin in the body.
K hurts no good DNA or cells and that is why it will mitigate some of the effects of current treatments that is akin to treating the body with Napalm (they kill everything including good cells).
The toxological tests on the Kevetrin pill are 50% done but no money to proceed further. When money becomes available and pill gets OK, then IPIX should be swamped by every current cancer treatment BP looking to update their treatment to make it less toxic and more effective and thus reset their patents of which many are due to expire soon.
Nothing wrong w/ K that a little spare cash won't solve.
Question is crazy IMO.
Either Brilacidin works or it doesn't. To more refine the possibilities, we have proof of safety by the trial moderators allowing for an expanded number of days of dosing and allowing Brilacidin to be used for Compassionate Use in CRITICAL patients. These critical patients have GREATLY depressed immune systems so a drug with any side effects would most likely do them in. Ergo, safety not a problem.
As to efficacy, either Brillacidin kills EVERY VIRUS or it kills none. Why would some virus cells be immune to it? This is not a hope to kill drug - it is a virus killer. When you shoot balloons with a .45 slug do you hope it breaks the balloon 10%, 50%, or 90% of the time. NO, it breaks it 100% of the time based on the laws of science.
Same thing with Brilacidin. It kills viruses all the time, not just part of the time. The SOC (both that used in the USA and Russia) does not KILL any viruses, they just stop or slow down their replication.
Only way this trial could be anything but a complete success IMO would be due to criminal activity on the part of those in the trial chain or in the administration side as in the FDA. This would be shown if the SOCs miraculously turn out to work wonderfully or Brilacidin to fail the viral load and stop the damage to vital organs to any degree.
IMO will finish wherever MMs want it to finish.
Until news they still run the show.
After great results, maybe their stranglehold on the share price will weaken quite a bit. If we have MAJOR volume, their stranglehold will diminish rapidly (though we will still have major spikes/dips as they try and clear their positions)
Attached is the Cold Spring Harbor Laboratory website. QUITE impressive!!
https://www.cshl.edu/
You just lost me with this political BS!
I think some of these MMs are fighting for their financial lives so that is why the push is on so hard today.
They have to know their goose is already cooked as IMO the only sales today (and I believe they are strictly MOMO players trading) are from traders and real longs are still holding as tight as ever. Also believe the VAST majority of shares traded today are "phantom" shares.
Disappointing though that these criminals keep repeating their plays over and over and over an yet the dumb retail trade keeps falling for it.
If they just held and waited the daily push down they would find the downward spiral would have been much, much weaker and far less lengthy.
Still believe the afternoon will see a very good rebound.
Orchestrated take down of the most obvious manner. Even the clueless SEC should be able to see this - though whether they care will be another matter (their pockets get stuffed, that is all they care about).
Those MMs facing financial ruin are hell bent for leather today to try and shake the tree before having to face the music next week. The gyrations of the bid/ask are near to comical and a disgrace in a supposed unbiased trading system.
I pity those losing their shares today NOT THE LEAST!! They were informed of this ploy last week and are obviously clueless as to the value of the science in which they invested. They deserve what they get.
We will see a nice bounce back this afternoon.